Aspirin was also associated with a 48% reduc- tion in the incidence of MI (2.8% versus 5.4%; P<0.001), a 50% reduction in the incidence of stroke (1.3% versus 2.6%; P=0.01), a 74% reduction in the incidence of renal failure (0.9% versus 3.4%; P<0.001), and a 62% reduction in the incidence of bowel infarction (0.3% versus 0.8%; P=0.01). Moreover, the authors reported that aspirin administration within 48 hours of surgery was safe, without an increase in the risk of hemorrhage, gastritis, infection, or impaired wound healing (odds ratio [OR] for adverse events, 0.63; 95% con- fidence interval [CI], 0.54 0.74).18 In a study assessing the impact of long-term postoperative aspirin therapy, Johnson found that CABG patients who consistently took aspi- rin over a 4-year period after surgery had significantly better long-term survival compared with those who did not (relative risk [RR] of death, 0.58; 95% CI, 0.47 0.70). Similar findings were noted in a long-term analysis of the CABG cohort of the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial, in which a lack of aspirin prescription at hospital discharge was identified as the strongest predictor of death at 4 years (hazard ratio [HR], With several trials featuring varied treatment protocols hav- ing been published in the literature, Fremes et al21 reviewed the impact of antiplatelet and anticoagulant therapy on vein graft patency in a meta-analysis of 17 randomized trials. 